Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $153.7 million.

  • Neurocrine Biosciences' Net Income towards Common Stockholders rose 4907.86% to $153.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $478.6 million, marking a year-over-year increase of 4022.85%. This contributed to the annual value of $478.6 million for FY2025, which is 4022.85% up from last year.
  • Neurocrine Biosciences' Net Income towards Common Stockholders amounted to $153.7 million in Q4 2025, which was up 4907.86% from $209.5 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Net Income towards Common Stockholders ranged from a high of $209.5 million in Q3 2025 and a low of -$76.6 million during Q1 2023
  • Over the past 4 years, Neurocrine Biosciences' median Net Income towards Common Stockholders value was $83.1 million (recorded in 2023), while the average stood at $77.8 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Net Income towards Common Stockholders skyrocketed by 15665.8% in 2024 and then plummeted by 8179.72% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Net Income towards Common Stockholders stood at $22.5 million in 2021, then soared by 556.44% to $147.7 million in 2023, then crashed by 30.2% to $103.1 million in 2024, then surged by 49.08% to $153.7 million in 2025.
  • Its last three reported values are $153.7 million in Q4 2025, $209.5 million for Q3 2025, and $107.5 million during Q2 2025.